Aspirin Reduces Liver Fat in Clinical Trial of the Most Common Cause of Chronic Liver Disease
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Department of Medicine
Contact Information
165 Cambridge Street
Suite 302
Boston,
MA
02114
Phone: 617-726-7872
Fax: 617-724-1122
Email: snigwekar@mgh.harvard.edu
My primary research focus is calciphylaxis (also known as calcific uremic arteriolopathy) and it aims to develop effective treatments and diagnostic tests for patients with calciphylaxis.
Calciphylaxis, a dermal arteriolar calcification disorder, has significant mortality and morbidity. I am leading multiple research studies in calciphylaxis patients. These studies address risk factors and pathogenesis of calciphylaxis and guide development and examination of novel treatments and diagnostic modalities for this highly fatal disease. Our team is currently enrolling patients in the first ever randomized controlled trial for calciphylaxis wherein we are testing vitamin K supplementation as a potential therapy. More details regarding this trial are available at Clinicaltrials.gov.Our team also aims to apply the knowledge gained from calciphylaxis research to investigate other forms of vascular calcifications.
I am also involved in the epidemiological and translational investigations in the areas of hyponatremia, nephrolithiasis and olfaction-malnutrition.
Learn more about the Calciphylaxis Program at Mass GeneralEvery day, our clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and advance patient care.
Calciphylaxis is a serious and rare disease. Your support of the program helps us learn more about the disease through to provide the best care.
We offer innovative, high-quality medical care, trains future medical leaders, and produces research that advances science and improves care.
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Researchers have identified numerous genetic clusters that may help explain why people with type 2 diabetes have different clinical presentations.
We reached out to investigators at Massachusetts General Hospital and asked them to give us one science-backed action people can take to improve their heart health.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
In this 12-month, placebo-controlled, randomized clinical trial of 26 well-treated persons with HIV without known CVD, eplerenone was associated with a significant reduction in arterial inflammation.
Blocking reductive stress in the liver may benefit people with conditions such as obesity and fatty liver disease.
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.